STOCK TITAN
  1. Home
  2. News
  3. ELOX

ELOXX PHARMACEUTICALS INC - $ELOX STOCK NEWS

Welcome to our dedicated page for ELOXX PHARMACEUTICALS news (Ticker: $ELOX), a resource for investors and traders seeking the latest updates and insights on ELOXX PHARMACEUTICALS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ELOXX PHARMACEUTICALS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ELOXX PHARMACEUTICALS's position in the market.

News
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Rhea-AI Summary
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with the minimum market value of listed securities requirement. The extension, until October 9, 2023, will allow the company to execute its plan to meet Nasdaq's standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.32%
Tags
none
-
News
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit
Rhea-AI Summary
Eloxx Pharmaceuticals has announced the publication of a study demonstrating the potential of its TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) for the treatment of colorectal cancer. The study shows that the novel RMA, ZKN-157, has demonstrated activity against subtypes of colorectal cancer, particularly the CMS2 subtype characterized by high MYC activity. This research opens up opportunities to selectively target MYC-driven cancers with a novel mechanism and potentially synergize with existing cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
-
News
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
clinical trial
News
Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
conferences
-
News
Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
none
-
News
Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.88%
Tags
clinical trial
News
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
News
Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.53%
Tags
clinical trial
-
News
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.67%
Tags
earnings
News
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.63%
Tags
none
Stock ELOX logo
ELOXX PHARMACEUTICALS INC

Nasdaq:ELOX

ELOX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ELOX Stock Data

3.21M
2.78M
0.41%
18.5%
0.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Waltham

About ELOX

eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin